Pneumagen's intranasal flu antiviral stands up to phase 2 human challenge study

Preview

来源: FierceBiotech

With the proof of concept in hand, Pneumagen now plans to advance more clinical trials for Neumifil to reduce viral exacerbations in patients with chronic obstructive pulmonary disease.

Pneumagen’s intranasal flu antiviral has stood up to the challenge—a human challenge study, that is. The Scottish company has found that Neumifil reduced the symptomatic infection rate and severity of viral respiratory tract infections during a phase 2 proof-of-concept trial.

Neumifil was tested in a rare human challenge study, where volunteers are intentionally given an infection and carefully monitored. The midstage trial featured 104 healthy adults who received two doses of the intranasal treatment before they were exposed to the influenza virus.

The therapy showed a clinically significant reduction in the incidence of symptomatic flu infection and in symptom severity, meeting the main goal of the trial. Neumifil was well tolerated, and there were no treatment-emergent adverse events or safety signals of note compared to an earlier phase 1 study, the company said.

With the proof of concept in hand, Pneumagen now plans to advance more clinical trials for Neumifil, including to reduce viral exacerbations in patients with chronic obstructive pulmonary disease, or COPD. A phase 2b trial is expected to get underway in 2024.

Neumifil is the lead therapy for St. Andrews, U.K.-based Pneumagen, which spun out of the University of St Andrews in Scotland. The company announced 8 million pounds sterling ($9.6 million) in financing in June to support the clinical development program.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。